NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Apertura Gene Therapy

Apertura Gene Therapy

Private
New York City, New YorkHealthcare & Life Scienceshttps://aperturagtx.com/

Last Round

Series A

Apr 26, 2022

Total Funding Raised

$67M

Company Overview

Apertura Gene Therapy is a biotechnology company that develops genetic medicines and next-generation AAV capsids designed to enable effective and selective gene delivery across the blood-brain barrier.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

gene therapycapsid engineeringblood-brain barrierBBB crossingcentral nervous systemCNSAAV capsidsviral vectorsbiotech platformrare disease researchdrug deliverybiotech licensingtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apertura Gene Therapy Comparables

Compare Apertura Gene Therapy with similar companies based on industry and business-model similarity.

Apertura Gene Therapy comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Dyno Therapeutics
84%
Capsida Biotherapeutics
84%
Shape Therapeutics
83%

Apertura Gene Therapy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 26, 2022

Key People

Founding team and executive leadership

Andrew Steinsapir

Acting Chief Technology Officer

Executive Team

Apertura Gene Therapy Investors

Notable investors and investment history

Apertura Gene Therapy investors
InvestorRounds
Deerfield ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 12, 2026

    Open Aperture provides researchers access to TfR1 CapX technology.

  • Jan 1, 2026

    Collaborating with Viralgen Vector Core to advance novel therapies.

Apertura Gene Therapy Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Apertura Gene Therapy Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Apertura Gene Therapy's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range8
Year Founded2021
Last FundingApr 26, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.